JP2015500335A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500335A5
JP2015500335A5 JP2014547135A JP2014547135A JP2015500335A5 JP 2015500335 A5 JP2015500335 A5 JP 2015500335A5 JP 2014547135 A JP2014547135 A JP 2014547135A JP 2014547135 A JP2014547135 A JP 2014547135A JP 2015500335 A5 JP2015500335 A5 JP 2015500335A5
Authority
JP
Japan
Prior art keywords
formula
compound
reaction
process according
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547135A
Other languages
English (en)
Japanese (ja)
Other versions
JP6456143B2 (ja
JP2015500335A (ja
Filing date
Publication date
Priority claimed from GBGB1121413.7A external-priority patent/GB201121413D0/en
Priority claimed from GBGB1201758.8A external-priority patent/GB201201758D0/en
Application filed filed Critical
Priority claimed from PCT/PT2012/000048 external-priority patent/WO2013089573A1/en
Publication of JP2015500335A publication Critical patent/JP2015500335A/ja
Publication of JP2015500335A5 publication Critical patent/JP2015500335A5/ja
Application granted granted Critical
Publication of JP6456143B2 publication Critical patent/JP6456143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547135A 2011-12-13 2012-12-12 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 Active JP6456143B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161570141P 2011-12-13 2011-12-13
GB1121413.7 2011-12-13
GBGB1121413.7A GB201121413D0 (en) 2011-12-13 2011-12-13 Chemical compounds and processes
US61/570,141 2011-12-13
US201261593625P 2012-02-01 2012-02-01
GB1201758.8 2012-02-01
GBGB1201758.8A GB201201758D0 (en) 2012-02-01 2012-02-01 Chemical compounds and processes
US61/593,625 2012-02-01
US201261718589P 2012-10-25 2012-10-25
US61/718,589 2012-10-25
PCT/PT2012/000048 WO2013089573A1 (en) 2011-12-13 2012-12-12 Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017207738A Division JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Publications (3)

Publication Number Publication Date
JP2015500335A JP2015500335A (ja) 2015-01-05
JP2015500335A5 true JP2015500335A5 (OSRAM) 2016-02-12
JP6456143B2 JP6456143B2 (ja) 2019-01-23

Family

ID=48612903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014547135A Active JP6456143B2 (ja) 2011-12-13 2012-12-12 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2017207738A Active JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2019214566A Withdrawn JP2020059729A (ja) 2011-12-13 2019-11-27 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017207738A Active JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2019214566A Withdrawn JP2020059729A (ja) 2011-12-13 2019-11-27 カテコール−o−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Country Status (15)

Country Link
US (2) US9126988B2 (OSRAM)
EP (2) EP3604299B1 (OSRAM)
JP (3) JP6456143B2 (OSRAM)
BR (1) BR112014014341A2 (OSRAM)
CA (2) CA3088684C (OSRAM)
CY (1) CY1122580T1 (OSRAM)
DK (1) DK2791134T3 (OSRAM)
ES (2) ES2758659T3 (OSRAM)
HR (1) HRP20192133T8 (OSRAM)
HU (1) HUE047856T2 (OSRAM)
PL (1) PL2791134T3 (OSRAM)
PT (2) PT2791134T (OSRAM)
RS (1) RS59666B1 (OSRAM)
SI (1) SI2791134T1 (OSRAM)
WO (1) WO2013089573A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
ES2597705T3 (es) 2007-01-31 2017-01-20 Bial - Portela & Ca., S.A. Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
KR102329271B1 (ko) 2009-04-01 2021-11-22 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PL2791134T3 (pl) * 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
GB2563858A (en) * 2017-06-27 2019-01-02 Azad Pharmaceutical Ingredients Ag New route of synthesis for opicapone
WO2019123066A1 (en) * 2017-12-18 2019-06-27 Unichem Laboratories Ltd Process for the preparation of opicapone and intermediates thereof
WO2020072884A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
US12097193B2 (en) 2018-10-05 2024-09-24 Bial—Portela & Ca, S.A. Methods for the administration of COMT inhibitors
CN109529881A (zh) * 2018-11-12 2019-03-29 刘晓菊 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル-ポルテラ エ コンパニア,ソシエダッド アノニマ 微粉化オピカポン
TW202200138A (zh) * 2020-05-26 2022-01-01 日商小野藥品工業股份有限公司 包含奧匹卡朋(opicapone)之錠劑
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
WO2022131944A1 (en) 2020-12-17 2022-06-23 Bial-Portela & Ca., S.A. Treatment regimens for early idiopathic parkinson's disease
CN112375014A (zh) * 2020-12-17 2021-02-19 重庆柳江医药科技有限公司 一种奥匹卡朋工艺杂质及制备方法和用途
WO2022180649A1 (en) * 2021-02-26 2022-09-01 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
GB202219669D0 (en) 2022-12-23 2023-02-08 Bial Portela & Ca Sa Processes and intermediates for synthesising opicapone
AU2023449890A1 (en) 2023-05-25 2025-11-27 Bial-Portela & Ca., S.A. Treatment regimens for early idiopathic parkinson's disease
WO2024260874A1 (en) * 2023-06-19 2024-12-26 Medichem, S.A. Process for preparing opicapone
WO2025012643A1 (en) 2023-07-11 2025-01-16 Tay Therapeutics Limited Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
CN119775271A (zh) * 2024-12-31 2025-04-08 南京海纳医药科技股份有限公司 一种奥吡卡朋粗品的精制方法
CN120081837A (zh) * 2025-02-14 2025-06-03 江苏天士力帝益药业有限公司 一种低单杂高纯度的奥匹卡朋中间体05的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4264573A (en) 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
US5206372A (en) 1990-06-05 1993-04-27 Shell Research Limited Preparation of 2-chloropyridine derivatives
DE69013689T2 (de) 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
AU3171493A (en) 1991-12-31 1993-07-28 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
CA2337755C (en) 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
ATE307129T1 (de) 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
DE60140213D1 (de) 2000-11-28 2009-11-26 Zymogenetics L L C Zytokine rezeptor zcytor19
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
PL369598A1 (en) 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
CN1638776A (zh) 2001-06-08 2005-07-13 西托维亚公司 取代的3-芳基-5-芳基-[1,2,4]-噁二唑和类似物
MXPA04000775A (es) 2001-07-26 2004-04-20 Merck Patent Ges Mit Baschrank Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
JP4379853B2 (ja) 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
AR045731A1 (es) 2003-08-06 2005-11-09 Vertex Pharma Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2006061697A1 (en) 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006071184A1 (en) 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
JP2008539195A (ja) 2005-04-26 2008-11-13 ノイロサーチ アクティーゼルスカブ 新規のオキサジアゾール誘導体及びそれらの医学的使用
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7553964B2 (en) 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1954137A4 (en) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
US8022075B2 (en) 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
ES2597705T3 (es) * 2007-01-31 2017-01-20 Bial - Portela & Ca., S.A. Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
EP2259777A2 (en) 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
EP2276758B1 (en) * 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
PT2307020T (pt) 2008-07-29 2019-05-28 Bial Portela & Ca Sa Regime de administração de nitrocatecólicos
KR102329271B1 (ko) 2009-04-01 2021-11-22 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
AU2010231962B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2011107653A2 (en) 2010-03-04 2011-09-09 Orion Corporation Method for treating parkinson's disease
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PL2791134T3 (pl) * 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy

Similar Documents

Publication Publication Date Title
JP2015500335A5 (OSRAM)
Qin et al. Rh (III)-catalyzed oxime ether-directed heteroarylation of arene through oxidative C–H/C–H cross-coupling
CN101020658B (zh) 喹诺酮主环化合物的合成方法
CN108863969B (zh) 一种4-烯丙基-3,5-二取代异噁唑的合成方法
CN103992356A (zh) 一种二茂铁基查尔酮与乙酰乙酸乙酯的Michael加成产物及其制备方法
KR101067069B1 (ko) 트리플루오로아세트산을 이용한 페난트리딘 유도체의 제조방법
CN102093355B (zh) 一种c-3酰基化吲哚嗪化合物及其制备方法
CN104262309B (zh) 一种色酮类衍生物及其合成方法
CN107935925B (zh) 一种多取代菲啶化合物的制备方法
CN106674040B (zh) 一种无溶剂无催化剂制备n-芳基酰胺的方法
CN103694182B (zh) 一种喹喔啉类化合物的制备方法
CN101781199A (zh) 一种o-酰基杯[4]芳烃的化学合成方法
WO2020155925A1 (zh) 一种硝基烷基喹喔啉或其衍生物、氨基烷基喹喔啉或其衍生物及其合成方法
CN102127014B (zh) 一种氮杂菲酮化合物及其制备方法
CN106518865B (zh) 一种1-烯基中氮茚衍生物的制备方法
CN103113297B (zh) 一种8-芳基-1-萘酰胺化合物及其制备方法
CN109535140A (zh) 一种基于肟酯与吲哚构建双吲哚取代二氢吡咯酮类衍生物的方法
CN106317065A (zh) 喹啉并杂环化合物的合成方法
CN109096139B (zh) 一种α-羰基酰胺衍生物的制备方法
CN105949108B (zh) 一种3-(4-甲氧基苯硫基)-1-甲基--1h-吡咯-2,5-二酮化合物的制备方法
CN110627732A (zh) 一种合成硝基喹喔啉或其衍生物以及氨基喹喔啉或其衍生物的方法
CN103467296B (zh) 一种3-溴-4-羟基苯甲酸甲酯的制备方法
CN104230719B (zh) 一种制备取代联苯的方法
CN110054589B (zh) 一种杂原子导向合成苯并喹啉酯类衍生物的合成方法
JP2012513391A5 (OSRAM)